Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 321

Similar articles for PubMed (Select 23665131)

1.

Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Hainsworth JD, Rubin MS, Arrowsmith ER, Khatcheressian J, Crane EJ, Franco LA.

Clin Genitourin Cancer. 2013 Sep;11(3):270-5. doi: 10.1016/j.clgc.2013.04.006. Epub 2013 May 9.

PMID:
23665131
2.

Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.

Rautiola J, Utriainen T, Peltola K, Joensuu H, Bono P.

Acta Oncol. 2014 Jan;53(1):113-8. doi: 10.3109/0284186X.2013.794957. Epub 2013 May 30.

PMID:
23721300
3.

Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.

Xie M, He CS, Huang JK, Lin QZ.

Eur J Cancer. 2015 Mar;51(5):595-603. doi: 10.1016/j.ejca.2015.01.005. Epub 2015 Jan 21.

PMID:
25618828
4.

High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.

Hainsworth JD, Shipley DL, Reeves J Jr, Arrowsmith ER, Barnes EK, Waterhouse DM.

Clin Genitourin Cancer. 2013 Sep;11(3):283-289.e1. doi: 10.1016/j.clgc.2013.04.014. Epub 2013 May 15.

PMID:
23684421
5.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK.

N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.

7.

[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].

Maráz A, Bodrogi I, Csejtei A, Dank M, Géczi L, Küronya Z, Mangel L, Petrányi A, Szûcs M, Bodoky G.

Magy Onkol. 2013 Sep;57(3):173-6. doi: MagyOnkol.2013.57.3.173. Epub 2013 Aug 9. Hungarian.

8.

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.

Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R.

J Clin Oncol. 2010 May 1;28(13):2131-6. doi: 10.1200/JCO.2009.26.3152. Epub 2010 Apr 5.

9.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ.

J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.

10.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.

J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416.

11.

Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.

Hess G, Borker R, Fonseca E.

Clin Genitourin Cancer. 2013 Jun;11(2):161-7. doi: 10.1016/j.clgc.2012.10.003. Epub 2012 Dec 23.

PMID:
23267717
12.

Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Keisner SV, Shah SR.

Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. Review.

PMID:
21395357
13.

Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK.

Clin Genitourin Cancer. 2014 Aug;12(4):262-9. doi: 10.1016/j.clgc.2014.03.002. Epub 2014 Mar 14.

PMID:
24795159
14.

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID.

Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12.

PMID:
23321547
15.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA.

N Engl J Med. 2007 Jan 11;356(2):115-24.

16.

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.

Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Wagner AJ, D'Adamo D, McMillan A, Demetri GD, George S.

Ann Oncol. 2014 Jan;25(1):236-40. doi: 10.1093/annonc/mdt484.

17.

Experience with pazopanib in the treatment of metastatic renal cell carcinoma: a monocentric experience.

Gernone A.

Tumori. 2014 Jul-Aug;100(4):165e-8e. doi: 10.1700/1636.17942.

PMID:
25296611
18.

Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.

Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ.

Clin Genitourin Cancer. 2013 Mar;11(1):45-50. doi: 10.1016/j.clgc.2012.06.001. Epub 2012 Oct 4.

PMID:
23041453
19.

Pazopanib outscores sunitinib on tolerability.

[No authors listed]

Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.

20.

Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.

Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK.

N Engl J Med. 2014 May 1;370(18):1769-70. doi: 10.1056/NEJMc1400731. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk